Co-targeting MERTK and EGFR with a Bispecific Antibody Overcomes Drug Resistance Across Mutations in Exons 19, 20, and 21
Giri, S.; Selvadurai, B.-R.; Simoni-Nieves, A.; Gupta, N.; Lindzen, M.; Chatterjee, R.; Genna, A.; Van-Daele, M.; Ramesh-Kumar, D.; Zerbib, M.; Oren, R.; Meijer, I. S.; Wippich, E. F.; Avraham, Y.; Dahan, R.; Kilpatrick, L. E.; Platt, S.; Hill, S. J.; Pal, L. R.; Ruppin, E.; Romaniello, D.; Lauriola, M.; Yarden, Y.
Show abstract
Resistance of lung cancer to EGFR-specific tyrosine kinase inhibitors (TKIs), such as osimertinib, often arises from secondary mutations or the activation of bypass signaling pathways. We noted elevated levels of GAS6 and its receptor, MERTK, in patients acquiring resistance to osimertinib, hence hypothesized that the GAS6-MERTK axis can serve as a therapeutic target. GAS6 promoted cell survival and an anti-GAS6 antibody we generated delayed tumor relapses in a xenograft model. Likewise, MERTK ablation sensitized lung cancer cells to osimertinib due to a newly described EGFR-to-MERTK crosstalk. Hence, we developed Bis3, a bispecific antibody targeting both MERTK and EGFR and promoting their degradation. Bis3 plus TKIs cooperatively inhibited the growth of TKI-resistant lung cancer spheroids and markedly delayed relapses of patient-derived xenografts harboring the clinically challenging exon-20 mutations. These findings establish the GAS6-MERTK axis as a driver of drug resistance and provide a rationale for clinical development of Bis3.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 98%
- Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures 97%
- Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot 97%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 97%
- Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer 96%
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 96%
Similar papers in this journal
- Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape 96%
- Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation 95%
- Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.